[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neck-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neck-cancer":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,82,111,140],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100644717","evaluating-the-optimal-timing-of-acupuncture-for-managing-chemoradiation-induced-xerostomia-in-patients-with-head-and-neck-cancers-100644717",false,"NCT07674706","Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","A Pilot Randomised Trial Evaluating the Optimal Timing of Acupuncture for Managing Chemoradiation-induced Xerostomia in Patients With Head and Neck Cancers","Inclusion Criteria:\n\nParticipants are eligible to be included in the study only if all the following criteria apply:\n\n1. Aged 21 years or older\n2. Oral cavity or oropharyngeal squamous cell carcinoma, or nasopharyngeal carcinoma planned for either curative adjuvant or definitive chemoradiotherapy using intensity-modulated radiation therapy (IMRT).\n\n   Participants who have received prior induction chemotherapy or are planned for adjuvant chemotherapy are not excluded.\n3. Anatomically intact parotid and submandibular glands\n4. Eastern Cooperative Oncology Group performance status of 0 to 2\n5. Able to provide informed consent\n6. A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies:\n\n   1. Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR\n   2. A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the acupuncture period and for at least 28 days after the last acupuncture.\n\nExclusion Criteria:\n\nParticipants are excluded from the study if any of the following criteria apply:\n\n1. History of xerostomia, Sjögren's disease, or another underlying systemic illness known to cause xerostomia\n2. Prior head and neck radiation treatment\n3. Has bleeding disorders (e.g. Hemophilia), or on anticoagulants (e.g. warfarin, low molecular weight heparin and novel oral anticoagulants)\n4. Upper or lower extremity deformities that could interfere with accurate acupoint location or alter the energy pathway as defined by traditional acupuncture theory.\n5. Local skin infections, lymphedema, or severe skin conditions (e.g., psoriasis, eczema) at or near the acupuncture sites\n6. Ongoing active systemic infection\n7. Current use of amifostine or cholinergic agonist medications (pilocarpine, cevimeline) that can affect salivary functions (salivary substitute not prohibited, but if using, they must refrain from using it for at least 24 hours prior to salivary flow assessment)\n8. Concurrent use of alternative medicines (e.g., Chinese Propriety medicines), that could affect salivary function\n9. Is pregnant or expecting to conceive within the projected duration of the trial, starting with the screening visit through 28 days after the last acupuncture treatment\n10. Low body mass index, ie. BMI \\\u003C 15\n11. Mental incapacitation or significant emotional or psychiatric disorder that, in the opinion of the investigator, may prevent the patient from cooperating with trial procedures","ALL","21 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","While existing data supports the use of acupuncture to reduce radiation-induced xerostomia, the optimal timing of acupuncture for managing chemoradiation-induced xerostomia remains an area of active investigation. Prior studies have administered acupuncture either in patients who developed xerostomia 12 months after radiation 10 or during the radiation therapy itself 9. The hypothesis is that acupuncture may be more effective in preventing and reducing xerostomia when administered early during CRT, rather than after chronic xerostomia has already set in. Yet, oncologists have concerns about the potentially higher risk of complications, such as infection, associated with acupuncture, especially if administered concurrently with chemoradiotherapy. Therefore, this study aims to conduct this randomised trial to evaluate the impact of early versus delayed acupuncture on patient-reported and objective measures of xerostomia, as well as the safety and tolerability of acupuncture in this setting.\n\nTo our knowledge, this will be the first randomised clinical trial evaluating the optimal timing for incorporating acupuncture to reduce xerostomia in patients undergoing chemoradiation for head and neck cancers. It is also the first study conducted in Singapore to study the role of acupuncture in reducing CRT-induced xerostomia.",[26,27,28,29,30,31],"Xerostomia","Head Cancer","Neck Cancer","Nasopharyngeal Carcinoma (NPC)","Oral Cavity Squamous Cell Carcinoma","Oropharyngeal Squamous Cell Carcinoma",[33],"Acupuncture","NOT_YET_RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2029-06",{"name":44,"class":45},"National University Hospital, Singapore","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":21,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100417962","phase-1-a-study-of-cemiplimab-with-chemotherapy-and-immunotherapy-in-people-with-head-and-neck-cancer-100417962","NCT04722523","A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","A Pilot Study of Neoadjuvant Cemiplimab With Platinum-Doublet Chemotherapy, and Cetuximab in Patients With Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma of the head and neck that has arisen from the oral cavity, oropharynx, nasal cavity, paranasal sinuses, larynx, or hypopharynx\n* Clinical stage T1, N2-3; T2, N1-3, T3\u002FT4a, Any N (AJCC, 8th ed.) without evidence of distant metastasis (M0) based on PET\u002FCT or CT chest, abdomen, and pelvis, for which standard-of-care treatment would entail surgical resection with adjuvant radiation +\u002F- chemotherapy.\n\n  ° Patients with recurrent and multiple primary head and neck cancers that are surgically resectable are eligible if the patient did not receive prior radiation or systemic therapy.\n* Disease must be amenable to surgical resection.\n* The patient must be a surgical candidate.\n\n  1. Hemoglobin \\> 9.0 g\u002FdL\n  2. Absolute neutrophil count (ANC) \\>1.5 x 10\\^9\u002FL\n  3. Platelet count \\>100 x 10\\^9\u002FL\n  4. Serum creatinine \\\u003C1.5 upper limit of normal (ULN) or estimated creatinine clearance (CrCl) \\>30 mL\u002Fmin\n  5. Adequate hepatic function:\n* Total bilirubin \\\u003C1.5 x upper limit of normal ULN)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both \\\u003C 3 x ULN\n* Alkaline phosphatase (ALP) \\\u003C2.5 x ULN Note: For patients with Gilbert syndrome, total bilirubin \\\u003C3x ULN. Upper central must be documented appropriately as past medical history.\n* Men and woman \\>18 years old\n* Eastern cooperative oncology group performance status \\\u003C 1\n\nExclusion Criteria:\n\n* Prior radiation and systemic therapy for a head and neck cancer.\n* Oral cavity cancer that is not amenable to surgical resection or the patient is not a surgical candidate.\n* Active or prior documented autoimmune or inflammatory disorders that have been treated with steroids or immunomodulator therapy in the past 5 years.\n\nExceptions: Patients with vitiligo, type 1 diabetes mellitus, and endocrinopathies (including hypothyroidism due to autoimmune thyroiditis) only requiring hormone replacement, childhood asthma that is resolved, or psoriasis it does not require systemic treatment are permitted.\n\n* Conditions requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalents) or other immunosuppressant medications within 14 days of treatment on study.\n* Receipt of live attenuated vaccine within 30 days prior initiating treatment on study.\n* Prior allogeneic stem cell transplantation, or autologous stem cell transplantation.\n* Any infection requiring hospitalization and\u002For intravenous antibiotic therapy within 2 weeks of the start of treatment.\n* Uncontrolled infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus (HBV or HCV) infection; or diagnosis of immunodeficiency.\n\n  1. Patients with known HIV infection who have controlled infection (undetectable viral load (HIV RNA PCR) and CD4 count above 350, either spontaneously or on a stable antiviral regimen) are permitted. For patients with controlled HIV infection monitoring will be performed per local standards\n  2. Patients with HBV (hepatitis B surface antigen positive; HBsAg+) who have controlled infection (serum HBV DNA PCR that is below the limit of detection and receiving anti-viral therapy for HBV) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months be on the last dose of Cemiplimab.\n  3. Patients were HCV antibody positive (HCV Ab+) who have controlled infection (undetectable HCV RNA by PCR, either spontaneously or in response to successful prior course of anti-HCV therapy) are permitted.\n* History of immune-related pneumonitis with the last 5 years.\n* History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of leuko-corticoids to assist with management.\n* Known hypersensitivity or allergy to any of the excipients in the cemiplimab drug product.\n* Patients with a history of solid organ transplant (exception: corneal transplant)\n* Any medical comorbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that in the opinion of the investigator renders the patient unsuitable for participation in a clinical trial due to high safety risks.\n* Women with a positive serum or urine beta-hCG pregnancy test at screening\u002Fbaseline visit. If positive, pregnancy must be ruled out by ultrasound for patient to be eligible.\n* Breast-feeding women\n* Women of childbearing potential who are sexually active and aren't willing to practice highly effective contraception prior to the first dose of Cemiplimab, during the study, and for at least 180 days after the last dose. Highly effective contraceptive measures include:\n\n  1. Stable use of combined estrogen and progesterone containing hormonal contraception or progesterone and-only hormonal contraception associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening\n  2. Intrauterine device; intrauterine hormone-releasing system\n  3. Bilateral tubal ligation\n  4. Vasectomized partner and\u002For\n  5. Sexual abstinence","18 Years",{"count":56,"type":20},40,[58],"PHASE1","The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.",[61,27,62,28,63,64],"Head and Neck Cancer","Head Cancer Neck","Head and Neck Squamous Cell Carcinoma","HNSCC",[66,67,68,61,27,28,63,69,70,71],"Cemiplimab","Platinum-Doublet Chemotherapy","Cetuximab","Memorial Sloan Kettering Cancer Center","20-445","HNSCC)","RECRUITING","2026-03-25",{"date":75,"type":38},"2026-03-30",{"date":77,"type":38},"2021-01-20",{"date":79,"type":20},"2026-06-20",{"name":69,"class":45},7,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":94,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100571611","exercise-and-nutritional-prehabilitation-for-head-and-neck-cancer-patients-100571611","NCT06722508","Exercise and Nutritional Prehabilitation for Head and Neck Cancer Patients","Inclusion Criteria:\n\nNew head and neck cancer diagnosis Age \\> 18\n\nExclusion Criteria:\n\n1. Prior treatment for head and neck cancer (surgery and\u002For radiation)\n2. Acute or unstable cardiac conditions (unstable angina or symptomatic severe aortic stenosis)\n3. American Society of Anesthesiologists physical status of 4 and 5\n4. Disabling orthopedic or neuromuscular disease\n5. Cardiac failure (New York Heart Association functional classes III and IV)\n6. Severe chronic obstructive pulmonary disease\n7. End-stage liver or kidney disease\n8. Inability to swallow and\u002For feeding tube dependence\n9. Any other comorbid medical, physical, and\u002For mental condition that contraindicates exercise or oral nutrition\n10. Adults unable to consent\n11. Age 17.99 or younger\n12. Prisoners, pregnant women, or other vulnerable population",{"count":89,"type":20},20,[23],"This study examines the acceptability, feasibility, and safety in developing a prehabilitation program for head and neck cancer patients. The purpose of this research is to access the safety and acceptability of using a prehabilitation program before head and neck cancer surgery.",[27,28,93,61],"Sarcopenia",[95,96,97,98,99,100],"Exercise","Nutritional","Prehabilitation","Head","Neck","Cancer","2026-01-12",{"date":103,"type":38},"2026-01-15",{"date":105,"type":38},"2024-05-09",{"date":107,"type":20},"2026-12",{"name":109,"class":45},"University of California, Davis",2,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":46},"100414235","neurosensorial-disorder-and-pain-in-oral-cavity-and-oropharynx-cancer-traited-patients-ocapa-100414235","NCT04673981","Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)","Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients","OCAPA","Inclusion Criteria:\n\n* Patient treated for an oral cavity and oropharynx tumor from at least one year and maximum five years.\n* Women or men upper 18 years old)\n* Patient with full consent, aware and signed\n* Patient cover by the French social security system\n\nExclusion Criteria:\n\n* Patient with mental disorder, psychologic, with a defect of comprehension to agree fully the protocol\n* Pregnant women or nursing\n* Patients who can't comply with the protocol\n* Participation refusal\n* Inable full age patient or under judicial protection",{"count":120,"type":20},120,[23],"Following preliminary studies carried out in our department on these subject and subjective findings during clinical examinations, it has been shown that pain is a symptom that is rarely reported following treatment. Instead, neurosensory disorders such as hypoesthesia and paresthesia are found.\n\nThe objective of the study is to map and qualitatively evaluate neurosensory disorders in patients treated for cancers of the oral cavity and oropharynx.",[27,28,124],"Chronic Pain",[126,127,128,129,130],"Hypoesthesia","Allodynia","Orofacial","Neuropathic pain","cancer","2025-08-25",{"date":133,"type":38},"2025-09-02",{"date":135,"type":38},"2020-07-31",{"date":137,"type":20},"2028-07",{"name":139,"class":45},"University Hospital, Clermont-Ferrand",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":4,"briefSummary":151,"conditions":152,"keywords":153,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":46},"100511986","association-between-tinnitus-and-hearing-loss-in-locally-advanced-head-and-neck-cancer-treated-by-radiotherapy-alone-or-with-chemotherapy-a-prospective-and-multicenter-study-100511986","NCT05946577","Association Between Tinnitus and Hearing Loss in Locally Advanced Head and Neck Cancer Treated by Radiotherapy Alone or With Chemotherapy: a Prospective and Multicenter Study","Association Between Tinnitus and Hearing Loss in Patients With Locally Advanced Head and Neck Cancer Treated by Concomitant Chemoradiotherapy or Exclusive Radiotherapy: a Prospective and Multicenter Study","AURACCO","Inclusion Criteria:\n\n* Patient with locally advanced or post-operative ENT cancer with high risk of recurrence\n* Patient ≥ 18 years\n* Absence of prior chemotherapy or radiotherapy\n* Patient eligible for chemotherapy with cisplatin according to the standard regimen: radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with chemotherapy with cisplatin 100 mg\u002Fm2 every 3 weeks (i.e. at week 1, 4 and 7)\n* Patient ineligible for cisplatin chemotherapy receiving:\n\n  * Either exclusive radiotherapy (age \\> 70 years, contraindication: renal failure, patient wearing a device): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks.\n  * either chemoradiotherapy with a chemotherapy protocol different from the standard scheme (due to a contraindication to cisplatin): radiotherapy delivering 60-70 Gy in 30-35 fractions spread over 6 to 7 weeks associated with non-standard chemotherapy ototoxic (cetuximab or carboplatin-5FU)\n\nExclusion Criteria:\n\n* Tinnitus grade ≥ 2 according to the SOMA-LENT scale\n* Patient fitted for hearing disorders\n* Significant cognitive disorders that may compromise the performance of the various assessments\n* Patients treated with weekly cisplatin\n* Patient's refusal to participate in research",{"count":149,"type":20},140,"OBSERVATIONAL","The aim of the AURACCO study is to evaluate the association between the onset of tinnitus and hearing loss in patients with locally advanced head and neck cancer treated by concomitant chemoradiotherapy or exclusive radiotherapy",[27,28],[154,64,155,156,157,158,159,160,161,162,163,164,165],"Head and neck cancer","Undifferentiated nasopharyngeal cancer","UCNT","Salivary gland cancer","Radiotherapy","Chemoradiotherapy","Radiochemotherapy","Chemotherapy","Cisplatin","Ototoxicity","Tinnitus","Hearing loss","2023-07-07",{"date":168,"type":38},"2023-07-14",{"date":170,"type":20},"2023-07",{"date":172,"type":20},"2026-09",{"name":174,"class":45},"Assistance Publique - Hôpitaux de Paris"]